964 related articles for article (PubMed ID: 33692091)
1. Tocilizumab for hospitalized patients with COVID-19.
Afra K; Chen LYC; Sweet D
CMAJ; 2021 Apr; 193(15):E521. PubMed ID: 33692091
[No Abstract] [Full Text] [Related]
2. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.
Rello J; Waterer GW; Bourdiol A; Roquilly A
Anaesth Crit Care Pain Med; 2020 Dec; 39(6):699-701. PubMed ID: 33115684
[No Abstract] [Full Text] [Related]
3. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab prescribing criteria for COVID-19 patients.
Al-Qaaneh AM; Al-Ghamdi FH
Hum Vaccin Immunother; 2021 Apr; 17(4):1128. PubMed ID: 33079613
[No Abstract] [Full Text] [Related]
5. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
6. The shortcomings of tocilizumab in COVID-19.
Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
[TBL] [Abstract][Full Text] [Related]
7. Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Mar; 384(9):e46. PubMed ID: 33657301
[No Abstract] [Full Text] [Related]
8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
9. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.
Cortegiani A; Ippolito M; Greco M; Granone V; Protti A; Gregoretti C; Giarratano A; Einav S; Cecconi M
Pulmonology; 2021; 27(1):52-66. PubMed ID: 32713784
[TBL] [Abstract][Full Text] [Related]
10. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
[TBL] [Abstract][Full Text] [Related]
11. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy.
Schulte EC; Sellner J
EBioMedicine; 2021 Nov; 73():103635. PubMed ID: 34656879
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
Samaee H; Mohsenzadegan M; Ala S; Maroufi SS; Moradimajd P
Int Immunopharmacol; 2020 Dec; 89(Pt A):107018. PubMed ID: 33045577
[TBL] [Abstract][Full Text] [Related]
15. IL-6 blockade for COVID-19: a global scientific call to arms.
Murthy S; Lee TC
Lancet Respir Med; 2021 May; 9(5):438-440. PubMed ID: 33676592
[No Abstract] [Full Text] [Related]
16. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
17. [COVID-19: Still a place for tocilizumab?].
Richier Q; Plaçais L; Lacombe K; Hermine O
Rev Med Interne; 2021 Feb; 42(2):73-78. PubMed ID: 33288230
[No Abstract] [Full Text] [Related]
18. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
19. Serum Concentrations of Interleukin 6 in the General Adult Population: Possible Implications for Anti-IL-6 Therapy in SARS-Cov-2 Infection and IL-6-Related Diseases.
Alende-Castro V; Alonso-Sampedro M; Gude F; Gonzalez-Quintela A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):75-78. PubMed ID: 32500858
[No Abstract] [Full Text] [Related]
20. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]